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Vascular endothelium expresses both the estrogen receptors (ERs) α and β, and ERα mediates development of early
atherosclerosis in male mice. This process is thought to be testosterone-dependent. We hypothesized that male
murine aortic endothelium produces robust levels of estradiol by aromatase conversion of testosterone, and that
regulation of this process is mediated by the presence of ERs, primarily ERα. Aortic endothelium was isolated from
ERα knockout (ERα -/-) and wild-type (ERα +/+) male mice and treated with testosterone or the 5α reduction
product dihydrotestosterone (DHT), with or without the P450 aromatase inhibitor anastrazole, or a non-specific
estrogen receptor antagonist. Aromatase gene expression and estradiol production were assayed. Treatment with
testosterone, but not DHT, caused increased aromatase expression and estradiol production in ERα +/+
endothelium that was attenuated by disruption of ERα in the ERα -/- group. Anastrazole inhibition of aromatase
reduced testosterone-induced aromatase expression and estradiol levels in both ERα -/- and ERα +/+ endothelium.
Antagonism of both ERs decreased testosterone-induced aromatase expression in both wild-type and knockout
groups. The effects of the receptor antagonist on estradiol production differed between the two groups, however,
with a reduction in estradiol release from the ERα +/+ cells and complete abolition of estradiol release from the
ERα -/- cells. Thus, estradiol production in vascular endothelium from male mice is robust, depends on the aromatic
conversion of testosterone and requires functional ERα to achieve maximal levels of estradiol generation. Local
vascular production of aromatase-mediated estradiol in response to circulating testosterone may affect ERα-
dependent mechanisms to increase susceptibility to early atheroma formation in male mice. This pathway may
have important therapeutic relevance for reducing the risk of atherosclerotic cardiovascular disease in human
males.Introduction
Atherosclerotic cardiovascular disease (ASCVD) remains
the leading cause of mortality for both men and women
in Western societies. However, disparity exists between
the incidence of cardiovascular disease in men and women
of similar age, as well as between menopausal and pre-
menopausal women (Kannel et al. 1976). Although the
mechanisms behind these discrepancies are yet poorly
understood, the observations suggest the gender dispar-
ities in development of ASCVD stem in part from gender-
related differences in sex hormones, primarily estrogen
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atheroprotective effects of estrogens in females. This
notion of atheroprotective estrogen has been assumed to
include males, but accumulating evidence indicates that
this simple paradigm does not accurately reflect the
complexity of hormonal regulation of vascular disease.
Sex hormones exert gender-specific effects, derived from
both variations in the levels of sex hormones and from
gender-related patterns of hormone and receptor tissue
distribution leading to gender-specific responses (Vitale
et al. 2009; Villablanca et al. 2004; Villablanca et al. 2009).
Estrogen production depends in large part on the en-
zymatic conversion of testosterone to estradiol by aro-
matase, a member of the cytochrome P450 family, which
is expressed in the vasculature (Villablanca et al. 2004;is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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levels generated by aromatase activity appear to play a
detrimental cardiovascular role in both female and male
animal and human models. Aromatase-deficient female
mice demonstrated enhanced cardiac mechanical function
in an acute ischemia/reperfusion model (Bell et al. 2011).
Work from our lab suggested the importance of estrogen
receptor α in mediating early atherogenesis in male mice
(Villablanca et al. 2004). In humans, circulating levels of
endogenous estradiol in apparently healthy, middle-aged
men positively correlate with carotid artery intima-media
thickness (Tivesten et al. 2006). Additionally, Sudhir and
colleagues noted increased susceptibility to early ASCVD
in one male individual expressing a mutation of the estro-
gen receptor (Sudhir et al. 1997). The interplay between
circulating estrogen levels, aromatase-derived production
of estrogen, and the downstream effects of estrogen recep-
tor signaling appears to significantly affect the health of
the vasculature in males.
In particular, estrogen receptor signaling plays important
roles in modulating both genomic and non-genomic
pathways that influence inflammatory status and other
cellular mechanisms connected with atherosclerotic in-
jury (Villablanca et al. 2010). The physiological effects
of estrogen are mediated by multiple known mecha-
nisms, including two classical receptors located in the
cytosol that translocate to the nucleus and act as tran-
scription factors upon ligand binding (ERα and ERβ,
encoded by the genes ESR1 and ESR2, respectively). In
addition, non-genomic signaling mechanisms include
plasma membrane-associated estrogen receptors α and
β, and an intracellular G-protein coupled receptor local-
ized to the endoplasmic reticulum (gpER, also known as
GPR30) (Meyer et al. 2009; Meyer & Barton 2009). Par-
ticular attention has been paid to the relative contribu-
tions of ERα and β to ASCVD pathophysiology.
Vascular tissues in both males and females express ERα
and β, although the precise gender differences in expres-
sion and distribution of these receptors among various cell
types and vascular beds are still unclear (Mendelsohn &
Karas 2005).
Our prior work demonstrated that ERα-mediated in-
creased susceptibility to development of early athero-
sclerotic lesions in male mice may function in a
testosterone-dependent fashion (Villablanca et al. 2004)
via local vascular production of estradiol, as it was not
dependent on circulating levels of lipids or testosterone,
suggesting local vascular effects. In order to directly test
this mechanism, we developed a unique study system
whereby we isolated and cultured aortic endothelium
from ERα deficient and sufficient male mice. The ERα
knockout mouse provides a convenient model to further
investigate the mechanisms by which testosterone affects
vascular tissues (Couse & Korach 1999) and the preciseinvolvement of ERα. We sought to establish the extent of
local vascular production of estradiol in an in vivo model
of male vessels where the endothelial contribution can be
defined, and to investigate whether the response to this
vascular estradiol pool is mediated by estrogen receptors,
principally ERα. Because our prior work identified a role
for the ERα in vascular atherosclerotic pathology in male
mice, we utilized male mice with disruption of ERα and
pharmacologic manipulation of hormone status to tease
out the interactions of direct effects of testosterone on
vascular endothelium, an issue which has not been
addressed systematically in the literature.
Methods
Animals
ERα knockout (ERαKO) mice, also known as ERαNeo
knockout mice, were used in this study. Heterozygous ani-
mals were obtained from Dr. Dennis Lubahn (University
of Missouri) and mated to yield progeny deficient in the
full-length ERα (ERα −/−) and wild-type littermate con-
trols having intact ERα (ERα +/+). ERα −/− animals are
deficient in the full-length wild-type ERα protein, and
their reproductive function is abolished. However, the
disrupting neo sequence used to generate the knockout
results in an alternative variant of ERα protein, which
retains residual low level estradiol binding activity but
lacks the specificity to be from either ERα or ERβ, and
animals are thus insensitive to estrogen (Couse et al.
1995; Kudwa & Rissman 2003). Mice were housed
under standard temperature conditions with a 12-hour
light/12-hour dark cycle in a humidity-controlled, dedi-
cated pathogen-free barrier facility at the University of
California, Davis. Experiments were performed in com-
pliance with NIH Guidelines and in accordance with
protocols approved by the University of California,
Davis Animal Care and Use Committee. Tail DNA from
progeny of heterozygous matings was obtained using
DNeasy spin columns (Qiagen, Valencia, CA) per the
manufacturer’s instructions, and PCR amplification was
used to distinguish homozygous mutants from heterozy-
gotes and from wild-type animals. Custom primers were
designed by Sigma Genosys (The Woodlands, TX). Primer
sequences to determine the presence of the targeted
ERα gene in homozygous mutants (a 649-bp fragment
only) and the wild-type gene in normal animals (a 239-bp
fragment only) were as follows: ERα −/− (KO) forward
5’-TGAATGAACTGCAGGACGAG-3’ and reverse 5’-
AATATCACGGGTAGCCAACG-3’; ERα +/+ (WT) for-
ward 5’-CTACGGCCAGTCGGGCAT-3’ and reverse
5’-AGACCTGTAGAAGGCGGGAG-3’.
Endothelial cell harvest and culture
ERα +/+ and ERα −/− littermate male mice at 4 months
of age were anesthetized with Nembutal (0.6% ip) and
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arch and thoracic aorta were exposed and visualized
through a ventral midline incision, and cleaned of adhe-
rent fat. The aorta was retrograde perfused with sterile
PBS, pH 7.4, and then with EBM Basal Medium Phenol
Red Free media (Lonza, Basel, Switzerland). A segment
of the thoracic aorta was excised and cut longitudinally,
taking care not to injure the endothelial layer, and used
for endothelial cell cultures. A summary of methods
used for culturing endothelial cells from the above
segments is given below.
Mouse aortic explants were placed in tissue culture
dishes coated with Matrigel (BD Biosciences, San Jose,
CA) and EBM Phenol Red Free media supplemented
with a SingleQuot kit (Lonza, Basel, Switzerland) and
10% HyClone defined fetal bovine serum (Thermo Fisher
Scientific, Pittsburgh, PA). Segments were placed in the
dishes such that the endothelial layer was in contact
with the Matrigel. Cultures were maintained at 37°C in a
humidified atmosphere with 5% CO2. Explants were
removed after the cells migrated out from them, and the
remaining cells were fed three times weekly with
supplemented EBM Phenol Red Free media (growth
media) for 4–6 weeks until confluent. Confluent cells
were subcultured at a 1:4 split ratio onto uncoated 6-well
plates, and used for experiments at P3 at 80-90%
confluency.Immunohistochemistry
In order to verify the endothelial nature of cells isolated
from the mice, immunohistochemical characterization
was first performed, demonstrating that the cells were
endothelial. Immunostaining for endothelial-specific von
Willebrand factor (vWF) was accomplished with a rat
anti-vWF antibody (1:50 dilution, Dako Cytomation,
Glostrup, Denmark). Cells were seeded on laminin-coated
coverslips (Sigma-Aldrich, St. Louis, MO) and fixed using
1% paraformaldehyde. The cells were incubated first with
primary vWF antibody, then with biotinylated secondary
antibody, and finally with avidin-biotin horseradish pero-
xidase. Staining was visualized with 3,3′-diaminobenzidine
(Vector Laboratories, Burlingame, CA), followed by
counterstaining with 10% Mayer’s hematoxylin. The cells
were then ethanol and xylene dehydrated and permanently
mounted in non-aqueous mounting medium, VectaMount
(Vector Laboratories, Burlingame, CA). To confirm that
there was no contamination with smooth muscle cells,
staining with a rat anti-mouse smooth muscle α-actin
antibody was performed (Dako Cytomation, Glostrup,
Denmark) as previously described (Martin-McNulty et al.
2007). Cultured endothelial cells stained positively for
vWF and did not show any contamination from smooth
muscle following actin staining (data not shown).Experimental treatments
Prior to experiments, cells were rendered quiescent by
incubation overnight with 2% HyClone charcoal-treated
fetal bovine serum (Thermo Fisher Scientific, Pittsburgh,
PA). The cells were then incubated for 48 hours at 37°C
with media, testosterone, 5α-dihydrotestosterone (DHT),
or vehicle control (0.1% ethanol), with or without
anastrazole (AK Scientific, Inc., Union City, CA) or ICI-
182,780 (Tocris Bioscience, Bristol, United Kingdom), a
selective estrogen receptor down-regulator.
RNA and quantitative real-time PCR
Following experimental treatments, culture media was
removed, TRI Reagent (Molecular Research Company,
Cincinnati, OH) added directly to the culture dishes,
and cells collected by scraping. Total RNA was obtained
using TRI Reagent according to the manufacturer’s in-
structions. Preparation of cDNA was accomplished
according to the manufacturer’s instructions for Super-
Script II RNase H- Reverse Transcriptase (Invitrogen,
Carlsbad, CA) using 4 ug total RNA.
Sample cDNAs were diluted 1:10 and analyzed in dupli-
cate using SYBR Green I Master Mix (Applied Biosystems,
Foster City, CA). D-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers were designed using Primer
Express (Applied Biosystems, Foster City, CA) and were
as follows: sense 5'-GCAACAGGGTGGTGGACCT-3'
and antisense 5'-GGATAGGGCCTCTCTTGCTCA-3'.
Primers for P450 aromatase were commercially obtained
(SABiosciences, Valencia, CA). Forward and reverse pri-
mers were added at a concentration of 4 uM (P450
aromatase) and 2 uM (GAPDH) for each reaction well.
Detection of gene transcript levels was performed using
the GeneAmp 7900 HT system (Applied Biosystems,
Foster City, CA). The thermal cycling program was as
follows: 1 second at 50°C, then thermal activation for
10 min at 95°C and 40 cycles of PCR (melting for 15 sec-
onds at 95°C, followed by annealing/extension for 1 mi-
nute at 60°C). Gene expression levels were normalized
to GAPDH levels for each sample and expressed as per-
cent change compared to media control. PCR products
were separated by electrophoresis on a 2% agarose gel
to verify amplification product size.
Estradiol ELISA assay
After the experimental treatments, the conditioned media
from the cell treatments were collected and briefly spun
to sediment the dead cells, if any. Supernatants were im-
mediately frozen at −80°C until further use. The concen-
tration of estradiol in the conditioned media (supernatant)
was assayed using an Estradiol Enzyme Immunoassay
(EIA) kit (Cayman Chemical, Ann Arbor, MI) according
to the manufacturer’s instructions. Each experimental
treatment was performed in duplicate and the resulting
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lysates were also tested, and no estradiol was detected in
the lysates.Statistical analyses
Experimental treatments were performed in duplicate
and assayed in duplicate for gene expression or estradiol
release. All values for estradiol production and P450 aro-
matase expression were expressed as means ± standard
error of the mean (SEM). Comparisons between study
groups were made using Student’s t-test for independent
samples (two-tailed), and ANOVA, using Microsoft
Office 2000 Excel software for PC (Microsoft, Redmond,
WA) and SigmaStat version 2.03 (Systat Software, Inc.,
San Jose, CA). Genotype (ERα −/− versus ERα +/+)
and hormone status (testosterone, anastrazole, ICI
antagonist) were the grouping variables. Correlations
between parameters were analyzed using simple linear
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Figure 1 Testosterone treatment upregulates P450 aromatase expres
and increases estradiol release from ERα +/+ cells. Aortic endothelial c
testosterone (1 nM or 1 uM) for 48 hours. Following treatment, total RNA w
aromatase gene. Gene expression levels were normalized to GAPDH and e
ascertain the amplification and integrity of the resulting qRT-PCR products,
P450 aromatase and bottom panel: GAPDH). Cell supernatants were collect
(panels C and D). Results are expressed as means ± SEM. ** p < 0.01 compaResults
Disruption of ERα attenuates P450 aromatase expression
and abolishes estradiol release in testosterone-treated
aortic endothelial cells from male mice
We first sought to determine whether and how direct
application of testosterone to aortic endothelial cells iso-
lated from ERα +/+ male mice affects estradiol release and
expression of P450 aromatase. As shown in Figure 1A and
C, testosterone treatment increased P450 aromatase ex-
pression and increased estradiol release from the ERα +/+
endothelium in a dose-dependent manner. Treatment
with the higher dose of testosterone (1 uM) caused in-
creases in aromatase expression and estradiol production
of 580% and 350% of control, respectively. Disruption of
the ERα accomplished by use of the ERα −/− mouse
resulted in attenuation of the increase in levels of P450
aromatase seen in response to testosterone treatment
(Figure 1B). Although P450 aromatase still increased in a
dose-dependent manner in the ERα −/− cells, this increase
was reduced by two- to three-fold at each dose of testos-
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as isolated and used for qRT-PCR analysis of expression of the P450
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red to vehicle control.
Villablanca et al. SpringerPlus 2013, 2:214 Page 5 of 10
http://www.springerplus.com/content/2/1/214mice. In addition, the ERα −/− condition resulted in near
complete abolishment of estradiol production (Figure 1D).
Reduction in P450 aromatase expression and estradiol
release in response to treatment with DHT is unchanged
following disruption of ERα in male murine aortic
endothelial cells
Testosterone can be further metabolized to either 5α-
dihydrotestosterone (DHT) by the reductive action of
the cytochrome P450 enzyme 5α-reductase, or converted
to 17β-estradiol by P450 aromatase. DHT is a more potent
form of testosterone and has greater androgen receptor
binding affinity than testosterone. We treated male murine
aortic endothelial cells with DHT to determine whether
the observed effects of testosterone on aromatase expres-
sion and estradiol release are specific to testosterone itself,
or mediated by estradiol generated downstream from
testosterone by the actions of aromatase. As shown in
Figure 2, increasing concentrations of DHT resulted in
decreased aromatase expression and decreased levels of
secreted estradiol, and the response to DHT was similar
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Figure 2 Dihydrotestosterone (DHT) treatment down regulates P450
production from murine ERα +/+ and ERα −/− male aortic endothelia
ERα −/− mice were treated with DHT (1 nM or 1 uM) for 48 hours. Followin
expression of the P450 aromatase gene. Gene expression levels were norm
control (panels A and B). To ascertain the amplification and integrity of the
agarose gel (inset, top panel: P450 aromatase and bottom panel: GAPDH).
ELISA analysis of estradiol release (panels C and D). Results are expressed athe highest concentration of DHT (1 uM), secreted
estradiol levels were completely abolished (Figure 2C
and D), while aromatase expression was reduced to less
than 20% of control values for both ERα +/+ and ERα −/−
groups (Figure 2A and B).
P450 aromatase inhibition reduces testosterone-induced
P450 aromatase expression and abolishes testosterone-
induced estradiol release from aortic endothelial cells
from both ERα wild-type and ERα knockout male mice
To further define the role of testosterone-derived estra-
diol in the mechanisms of estradiol release from aortic
endothelium, we then co-incubated isolated cells with
testosterone and an aromatase inhibitor, anastrazole
(Figure 3). Endothelial cells derived from ERα +/+ male
animals demonstrated reduced aromatase expression
and no estradiol secretion in response to treatment with
both testosterone and anastrazole (Figure 3A and C),
compared to the dose-dependent increases in aromatase
and estradiol described in response to testosterone alone.
A similar trend was observed for the ERα −/− cells, where
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aromatase expression and protein levels, and reduces estradiol
l cells. Aortic endothelial cells isolated from male ERα +/+ and
g treatment, total RNA was isolated and used for qRT-PCR analysis of
alized to GAPDH and expressed as percent change compared to
resulting qRT-PCR products, the products were separated on a 2%
Cell supernatants were collected following treatment and used for
s means ± SEM. ** p < 0.01 and * p < 0.05 compared to vehicle control.
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Figure 3 The P450 aromatase inhibitor, anastrazole, reduces testosterone-induced P450 aromatase expression and estradiol
production in murine ERα +/+ and ERα −/− male aortic endothelial cells. Aortic endothelial cells isolated from male ERα +/+ and ERα −/−
mice were treated with testosterone (100 nM or 1 uM) with or without 100 nM anastrazole for 48 hours. Following treatment, total RNA was
isolated and used for qRT-PCR analysis of expression of the P450 aromatase gene. Gene expression levels were normalized to GAPDH and
expressed as percent change compared to control (panels A and B). To ascertain the amplification and integrity of the resulting qRT-PCR
products, the products were separated on a 2% agarose gel (inset, top panel: P450 aromatase and bottom panel: GAPDH). Cell supernatants were
collected following treatment and used for ELISA analysis of estradiol release (panels C and D). Results are expressed as means ± SEM. ** p < 0.01
and * p < 0.05 compared to vehicle control.
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ment of estradiol release. Although testosterone treatment
alone generated much lower levels of aromatase expres-
sion and estradiol release from ERα −/− endothelial
cells compared to ERα +/+ cells, the reduction in levels
of aromatase expression following anastrazole treatment
(30-80% compared to testosterone alone) were not sig-
nificantly different between the ERα −/− and ERα +/+
groups. There was also no estradiol production in endo-
thelium from ERα −/− and ERα +/+ male mice following
anastrazole.
Testosterone-induced P450 aromatase expression and
estradiol release from ERα wild-type and ERα knockout
male aortic endothelial cells are attenuated by estrogen
receptor antagonism
As our murine model addressed the contribution of the
ERα using the knockout model, but did not address the
contribution of the ERβ, we assessed the contribution of
each receptor and investigated how blocking both recep-
tors would influence the effects of testosterone on aortic
endothelial estrogen production. The estrogen receptor
antagonist ICI-182,780 was used to block both ERα andERβ. ICI-182,780 primarily down-regulates ERα, and to a
lesser extent ERβ (Pike et al. 2001). As shown in Figure 4,
antagonism of estrogen receptors by ICI-182,780 reduced
aromatase expression in the presence and absence of
testosterone in both ERα +/+ and ER −/− animals. In ERα
+/+ cells, the antagonist alone reduced aromatase expres-
sion to 3% of control, while in the presence of testoster-
one, the antagonist reduced aromatase expression to 21%
of control (Figure 4A). In the ERα −/− group, the antagon-
ist alone reduced aromatase expression to 29% of control,
while the antagonist plus testosterone reduced expression
to 25% of control (Figure 4B). Estrogen receptor inhibition
had no effect on estradiol release compared to control
conditions in endothelium from ERα +/+ mice, but de-
creased testosterone-induced estradiol to baseline values
(Figure 4C). In contrast, pharmacological blockade of es-
trogen receptors in ERα −/− mice completely abolished
estradiol release both with and without testosterone
stimulation.
Discussion
Although estrogen’s effects on the vasculature are gener-
ally accepted to be atheroprotective in females, there is
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Figure 4 Antagonism of both estrogen receptors α and β attenuates testosterone-induced P450 aromatase expression and estradiol
release from murine ERα +/+ and ERα −/− male aortic endothelial cells. Aortic endothelial cells isolated from male ERα +/+ and ERα −/−
mice were treated with testosterone (1 uM) with or without 300 nM ICI-182,780 (selective estrogen receptor down-regulator that primarily down-
regulates ERα, and to a lesser extent ERβ) for 48 hours. Following treatment, total RNA was isolated and used for qRT-PCR analysis of expression
of the P450 aromatase gene. Gene expression levels were normalized to GAPDH and expressed as percent change compared to control (panels
A and B). To ascertain the amplification and integrity of the resulting qRT-PCR products, the products were separated on a 2% agarose gel (inset,
top panel: P450 aromatase and bottom panel: GAPDH). Cell supernatants were collected following treatment and used for ELISA analysis of
estradiol release (panels C and D). Results are expressed as means ± SEM. ** p < 0.01 and * p < 0.05 compared to vehicle control; ns = not
significant.
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mone effects as they relate to cardiovascular disease
risk and sex. To further investigate the role of estrogen
in the male vasculature, we sought to determine
whether and how estrogen is locally produced by male
endothelium, the level of production, and the estrogen
receptor (principally α) dependence utilizing endothe-
lial cells derived from aortic explants from ERα wild-
type (+/+) and knockout (−/−) male mice. In this
unique study system, we have characterized the level of
endothelial testosterone-enhanced estradiol produc-
tion and identified an estrogen receptor-dependent op-
erative mechanism. Our results demonstrate that male
aortic endothelial cells do indeed produce relatively
large quantities of estrogen, and this process proceeds
through the enzymatic conversion of testosterone by
P450 aromatase. In addition, ERα plays a primary role
in this pathway by contributing to increased aromataseexpression and estradiol release, with a lesser contribution
from ERβ.
Testosterone is the primary sex steroid present in
males, although there are appreciable quantities of estro-
gen present in the circulation. In males, the enzymatic
conversion of testosterone by P450 aromatase through-
out the body provides the major source of estrogen.
Previous studies including our own have demonstrated
the presence of aromatase in various tissues, including
the vascular endothelium (Villablanca et al. 2004;
Murakami et al. 2001; Nathan et al. 2001). Estrogen at
the level of the vasculature is customarily thought of as
atheroprotective due to its ability to exert anti-
inflammatory and anti-atherogenic effects. Epidemio-
logical and observational studies originally noted decreased
incidence of cardiovascular disease in pre-menopausal
women compared to age-matched men (Kannel et al.
1976; Regitz-Zagrosek 2006; Störk et al. 2004).
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protective effects of estrogen in models of cardiovascular
injury (Brouchet et al. 2001; Pare et al. 2002; Dean et al.
2005). Some cell culture models also provide evidence
of the anti-inflammatory and anti-atherogenic roles of
estrogen (Mori et al. 2004; Florian & Magder 2008), but
these do not provide a conclusive understanding, as
other cell experiments demonstrate the opposite effects
of estrogen, including upregulation of inflammatory
markers in endothelial cells co-stimulated with tumor
necrosis factor-α (Zhang et al. 2002a; Zhang et al.
2002b). The vast majority of evidence supporting estro-
gen’s vasculoprotective role has been generated in fe-
male models, and the conflicting cellular results from
experiments where the sex of the donor is often un-
known suggest the importance of independently investi-
gating the male response before assuming similarity
between males and females.
To begin addressing these sex-specific differences, we
first sought to determine whether murine male aortic
endothelium could produce estradiol under basal condi-
tions and in the presence of testosterone. Under control
conditions very little estradiol was generated; however,
testosterone stimulation caused a large increase in the
production of estradiol (to over 400 pg/ml) that was
completely abolished by co-incubation with an aroma-
tase inhibitor, anastrazole, suggesting that local vascular
production of estrogen is dependent on the activity of
aromatase in male mice. Our findings correlate well with
previous studies demonstrating the necessity of aromatase
for estrogen-mediated effects in male tissues (Sun et al.
2007; Sierra-Ramirez et al. 2004; Kimura et al. 2003). Fur-
ther, when we treated cells with 5α-dihydrotestosterone
(DHT), a form of testosterone that cannot be converted to
estradiol by aromatase, we did not observe any estradiol
production by aortic endothelial cells derived from either
the ERα +/+ or ERα −/− animals. This lends support to
our conclusion that vascular production of estradiol in
male mice depends on the P450 aromatase-driven conver-
sion of testosterone.
In response to testosterone stimulation, gene expression
of aromatase increased in a dose-dependent manner in
both the ERα +/+ and ERα −/− endothelial cells, but was
reduced in the ERα −/− group compared to the ERα +/+
cells. The partial ERα gene present in the ERα −/− mice
may be responsible for this persistent partial upregulation
of aromatase in ERα −/− mice in the presence of testoster-
one. Our studies with the selective estrogen receptor
(alpha greater than beta) down-regulator, ICI-182,780, also
support this interpretation. Testosterone-induced estradiol
release from ERα −/− endothelium also was significantly
attenuated compared to ERα +/+ endothelium, suggesting
involvement of the ERα in the aromatase-mediated mech-
anism of estradiol release as well. Others have shownsimilar intricate connections between ERα, aromatase, and
estradiol in other biological systems. In hippocampal neu-
rons for example, aromatase-mediated estrogen produc-
tion appears to be involved in an auto/paracrine feedback
mechanism to regulate ERα and β expression (Prange-Kiel
et al. 2003). Additionally, Kinoshita and Chen demon-
strated the necessity of ERα in estrogen-mediated aroma-
tase activity in human breast cancer cells (Kinoshita &
Chen 2003).
Pharmacological inhibition of both classical ERs by a
selective estrogen receptor down-regulator helped to
further define the relative contributions of ERα and β to
estrogen-induced responses in the aortic endothelium of
male mice. We observed attenuation of testosterone-
induced estradiol production in the ERα +/+ endothelium
in the presence of the antagonist, and interestingly,
complete abolishment of estradiol production in response
to testosterone stimulation in the ERα −/− cells with the
antagonist. We interpret these results to indicate that the
presence of functional ERα helps maintain baseline levels
of aromatase available to generate estradiol. Antagonism
of both ERα and β in the ERα +/+ group reduced
testosterone-stimulated estradiol levels to control values,
but the presence of the intact ERα appears to have previ-
ously primed the cells such that they were able to produce
baseline levels of estrogen even in the presence of the
antagonist. However, the absence of ERα seems to leave
the cells deficient in their ability to produce baseline levels
of estrogen, and inhibiting the remaining ERβ completely
prevents estradiol release as observed in the ERα −/−
group. Based on our results, we estimate that approxi-
mately two thirds of the estradiol produced in response to
testosterone stimulation in male wild-type mice is due
to the presence of ERα, and the remaining one third is
due to the presence of ERβ. However, the possible role
for ERβ requires future work with endothelium from
ERβ knockout mice and/or specific ERβ inhibitors.
The results reported here demonstrate the importance
of ERα and P450 aromatase in mediating testosterone-
induced estradiol release from male murine aortic endo-
thelium. Our previous findings demonstrated increased
susceptibility to early atherosclerotic vascular changes in
male mice mediated by the ERα and suggested likely
dependence on testosterone (Villablanca et al. 2004). Al-
though this present study was not intended to address
atherogenesis, in the context of our prior studies, our
findings suggest that the mechanism for early atherogenesis
in ERα −/− male mice could indeed be explained by local
vascular estrogen production. This proposed mechanism is
in contrast to the findings of other groups, such as those
demonstrating aromatase-mediated anti-inflammatory
effects of testosterone (Mukherjee et al. 2002). However,
it is important to note the female origin of the models
used for these studies, which likely display different
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Work by Chakrabarti et al. suggests a complicating fac-
tor may lie in how the different types of estrogen recep-
tors respond upon estrogen binding, as their results
demonstrate that anti-inflammatory estrogen signaling
through the gpER in human umbilical vein endothelial
cells is complicated by concomitant signaling through
ERs α and β serving to attenuate estrogen’s anti-
inflammatory response (Chakrabarti & Davidge 2012).
The question necessitates future studies to unravel the
complex interactions between the many different estrogen
receptors and determine how these interactions differ
between males and females.
Although a number of previous studies have demon-
strated testosterone-driven regulation of early atherogenic
events in vascular endothelium (Nathan et al. 2001;
Mukherjee et al. 2002), to our knowledge, our report is
the first to demonstrate the level of robustness of estradiol
production by male mouse endothelium. In addition, we
demonstrated that regulation of this process depends not
only on the aromatic conversion of testosterone, but also
on the presence of a functional ERα. Although earlier
work suggested that human endothelium did not express
aromatase (Harada et al. 1999), subsequently P450 aroma-
tase expression was demonstrated in a variety of vascular
tissues in humans (Murakami et al. 2001; Mukherjee et al.
2002; Dietrich et al. 2011; Diano et al. 1999; Sasano et al.
1999), thereby establishing the biologic relevance of our
work in a murine system to the human vasculature. The
results of our studies in murine endothelium therefore
provide an additional model of investigation regarding
gender-specific differences in the hormonal regulation of
vascular disease.
The issue of gender differences in endothelium is com-
plex, and the results reported herein raise an interesting
question about the physiological relevance of locally-
produced estrogen in males. It remains unclear whether
estrogen generated at the level of the vascular endothe-
lium contributes deleterious cardiovascular effects in
males. It is also unclear whether aromatase activity and
testosterone action differ between endothelial vascular
beds (e.g., coronary endothelium, aortic endothelium, etc.)
and across animal species (e.g., mouse, rat, other) (Sierra-
Ramirez et al. 2004). There are reported differences
amongst animal species, sex, and the nature of the vascu-
lar endothelium being studied. Further work is clearly
needed in this important and interesting area of study to
fully unravel the mechanisms underlying the complexity
observed by our studies and those of prior investigators. It
will be important to pursue future studies aimed at inves-
tigating why male endothelium expresses aromatase and
produces estrogen, and the significance of these mecha-
nisms as they relate to atheroma formation in males. Our
work has direct clinical relevance, as it emphasizes thenecessity of exploring gender-specific differences in sex
hormone-related effects on vascular health, and suggests
ERα-dependent mechanisms as potential therapeutic
targets to decrease risk of atherosclerotic cardiovascular
disease, not only in females, but also in males.
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